Top Suppliers:I want be here


1879965-80-6

1879965-80-6 structure
1879965-80-6 structure
  • Name: E7090 succinate
  • Chemical Name: E7090 succinate
  • CAS Number: 1879965-80-6
  • Molecular Formula: C36H43N5O10
  • Molecular Weight: 705.765
  • Create Date: 2020-01-12 20:07:37
  • Modify Date: 2025-09-23 17:29:09
  • E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM); inhibits only 3 tyrosine kinases (RET, DDR2, and FLT1) with IC50 lower than 10 nM among the 93 kinases, also potently inhibits mutant FGFR3 (K650E and K650M, IC50=3.1 and 16 nM); inhibits FGFR phosphorylation and cell proliferation of SNU-16 cells with IC50 of 1.2 and 5.7 nM, respectively; shows selective antiproliferative activity against cancer cell lines harboring FGFR abnormalities, exhibits antitumor activity and inhibits FGFR signaling in a mouse xenograft model of SNU-16 human gastric cancer. Solid Tumors Phase 1 Clinical

Name E7090 succinate
Description E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM); inhibits only 3 tyrosine kinases (RET, DDR2, and FLT1) with IC50 lower than 10 nM among the 93 kinases, also potently inhibits mutant FGFR3 (K650E and K650M, IC50=3.1 and 16 nM); inhibits FGFR phosphorylation and cell proliferation of SNU-16 cells with IC50 of 1.2 and 5.7 nM, respectively; shows selective antiproliferative activity against cancer cell lines harboring FGFR abnormalities, exhibits antitumor activity and inhibits FGFR signaling in a mouse xenograft model of SNU-16 human gastric cancer. Solid Tumors Phase 1 Clinical
References References 1. Watanabe Miyano S, et al. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. View Related Products by Target FGFR Solid Tumors
Molecular Formula C36H43N5O10
Molecular Weight 705.765
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.